Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
21.11
+0.11 (0.52%)
At close: Apr 28, 2026, 4:00 PM EDT
21.50
+0.39 (1.85%)
After-hours: Apr 28, 2026, 6:39 PM EDT
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Syndax Pharmaceuticals stock have an average target of 38.69, with a low estimate of 17 and a high estimate of 57. The average target predicts an increase of 83.28% from the current stock price of 21.11.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 8 | 8 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $28 → $34 | Strong Buy | Maintains | $28 → $34 | +61.06% | Apr 1, 2026 |
| Mizuho | Mizuho | Buy Maintains $45 → $43 | Buy | Maintains | $45 → $43 | +103.69% | Mar 31, 2026 |
| Jefferies | Jefferies | Strong Buy Initiates $48 → $40 | Strong Buy | Initiates | $48 → $40 | +89.48% | Mar 30, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $33 → $45 | Buy | Maintains | $33 → $45 | +113.17% | Mar 9, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $51 → $57 | Strong Buy | Maintains | $51 → $57 | +170.01% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
357.10M
from 172.35M
Increased by 107.19%
Revenue Next Year
506.65M
from 357.10M
Increased by 41.88%
EPS This Year
-1.88
from -3.29
EPS Next Year
-0.36
from -1.88
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 453.7M | 705.3M | |||||
| Avg | 357.1M | 506.7M | |||||
| Low | 227.4M | 293.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 163.2% | 97.5% | |||||
| Avg | 107.2% | 41.9% | |||||
| Low | 31.9% | -17.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | -0.71 | 1.48 | |||||
| Avg | -1.88 | -0.36 | |||||
| Low | -2.71 | -1.96 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | - | |||||
| Avg | - | - | |||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.